AZ has struggled to extend the label of Imfinzi beyond that in NSCLC, other than a 2022 approval for the drug in combination with its CTLA4 inhibitor Imjudo (tremelimumab) for patients with ...

In August, the FDA accepted and granted a priority review to AZN’s regulatory filing seeking label expansion for Imfinzi in patients with LS-SCLC. The FDA had also granted a breakthrough therapy ...

At ASCO, AZ reported the full data from its DUO-O study of PD-L1 inhibitor Imfinzi (durvalumab ... Last year, for example, the label for GSK’s PARP Zejula (niraparib) was narrowed to BRCA ...